SlowBull
The Business Brief WEDNESDAY, 12 AUGUST 2026
← All stories
Markets

Boulevard starts up with $65M to pursue targeted autoimmune drugs

1 source ·1 article ·4h ago

Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·4h ago

Boulevard starts up with $65M to pursue targeted autoimmune drugs

Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.